Cargando…

A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Huangqi Guizhi Wuwutang granule in patients with rheumatoid arthritis

BACKGROUND: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by swelling, pain, and synovial damage. Effective methods lack in the treatment of RA. A traditional prescription in use for thousands of years in China, Huangqi Guizhi Wuwutang granule (HGWG) is still chosen to reli...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yiru, Liu, Yang, Xi, Zhijie, Yu, Yang, Liu, Li, Mao, Jianchun, Xiao, Lianbo, Gu, Xiaohua, Yao, Min, Cui, Xuejun, Shi, Qi, Wang, Yongjun, Liang, Qianqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426547/
https://www.ncbi.nlm.nih.gov/pubmed/30882703
http://dx.doi.org/10.1097/MD.0000000000014888
_version_ 1783405026631221248
author Wang, Yiru
Liu, Yang
Xi, Zhijie
Yu, Yang
Liu, Li
Mao, Jianchun
Xiao, Lianbo
Gu, Xiaohua
Yao, Min
Cui, Xuejun
Shi, Qi
Wang, Yongjun
Liang, Qianqian
author_facet Wang, Yiru
Liu, Yang
Xi, Zhijie
Yu, Yang
Liu, Li
Mao, Jianchun
Xiao, Lianbo
Gu, Xiaohua
Yao, Min
Cui, Xuejun
Shi, Qi
Wang, Yongjun
Liang, Qianqian
author_sort Wang, Yiru
collection PubMed
description BACKGROUND: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by swelling, pain, and synovial damage. Effective methods lack in the treatment of RA. A traditional prescription in use for thousands of years in China, Huangqi Guizhi Wuwutang granule (HGWG) is still chosen to relieve pain and prevent joint malformation in RA patients. However, no evidence-based medical research has been organized to assess the effectiveness and safety of HGWG for RA. METHODS/DESIGN: We will conduct a multicenter, randomized, double-blind, placebo-controlled clinical trial to determine whether HGWG can relieve pain and protect joints. We will randomly divide 120 patients with active RA into 2 groups, treated for 12 weeks. Main measurement is the rate of ACR50 score (American College of Rheumatology) from the baseline to 12 weeks. Secondary measurements include rate of ACR20/70, change of Disease Activity Score (DAS) 28, Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient Assessment of Arthritis Pain, Patient Global Assessment of Arthritis, and AIS score. The time points are set as baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 24 weeks, and 48 weeks. In addition, the rate of ACR50 from the baseline to 2 weeks, 4 weeks, 8 weeks, 24 weeks, and 48 weeks’ follow-up are also the secondary outcome measures. DISCUSSION: The findings of this research will elucidate the efficacy and safety of HGWG and provide an alternative treatment for RA. In addition, our data will benefit the clinical decision-making on active RA and possibly be incorporated into future guidelines. TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT03593837.
format Online
Article
Text
id pubmed-6426547
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-64265472019-04-15 A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Huangqi Guizhi Wuwutang granule in patients with rheumatoid arthritis Wang, Yiru Liu, Yang Xi, Zhijie Yu, Yang Liu, Li Mao, Jianchun Xiao, Lianbo Gu, Xiaohua Yao, Min Cui, Xuejun Shi, Qi Wang, Yongjun Liang, Qianqian Medicine (Baltimore) Research Article BACKGROUND: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by swelling, pain, and synovial damage. Effective methods lack in the treatment of RA. A traditional prescription in use for thousands of years in China, Huangqi Guizhi Wuwutang granule (HGWG) is still chosen to relieve pain and prevent joint malformation in RA patients. However, no evidence-based medical research has been organized to assess the effectiveness and safety of HGWG for RA. METHODS/DESIGN: We will conduct a multicenter, randomized, double-blind, placebo-controlled clinical trial to determine whether HGWG can relieve pain and protect joints. We will randomly divide 120 patients with active RA into 2 groups, treated for 12 weeks. Main measurement is the rate of ACR50 score (American College of Rheumatology) from the baseline to 12 weeks. Secondary measurements include rate of ACR20/70, change of Disease Activity Score (DAS) 28, Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient Assessment of Arthritis Pain, Patient Global Assessment of Arthritis, and AIS score. The time points are set as baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 24 weeks, and 48 weeks. In addition, the rate of ACR50 from the baseline to 2 weeks, 4 weeks, 8 weeks, 24 weeks, and 48 weeks’ follow-up are also the secondary outcome measures. DISCUSSION: The findings of this research will elucidate the efficacy and safety of HGWG and provide an alternative treatment for RA. In addition, our data will benefit the clinical decision-making on active RA and possibly be incorporated into future guidelines. TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT03593837. Wolters Kluwer Health 2019-03-15 /pmc/articles/PMC6426547/ /pubmed/30882703 http://dx.doi.org/10.1097/MD.0000000000014888 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle Research Article
Wang, Yiru
Liu, Yang
Xi, Zhijie
Yu, Yang
Liu, Li
Mao, Jianchun
Xiao, Lianbo
Gu, Xiaohua
Yao, Min
Cui, Xuejun
Shi, Qi
Wang, Yongjun
Liang, Qianqian
A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Huangqi Guizhi Wuwutang granule in patients with rheumatoid arthritis
title A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Huangqi Guizhi Wuwutang granule in patients with rheumatoid arthritis
title_full A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Huangqi Guizhi Wuwutang granule in patients with rheumatoid arthritis
title_fullStr A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Huangqi Guizhi Wuwutang granule in patients with rheumatoid arthritis
title_full_unstemmed A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Huangqi Guizhi Wuwutang granule in patients with rheumatoid arthritis
title_short A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Huangqi Guizhi Wuwutang granule in patients with rheumatoid arthritis
title_sort multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of huangqi guizhi wuwutang granule in patients with rheumatoid arthritis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426547/
https://www.ncbi.nlm.nih.gov/pubmed/30882703
http://dx.doi.org/10.1097/MD.0000000000014888
work_keys_str_mv AT wangyiru amulticenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT liuyang amulticenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT xizhijie amulticenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT yuyang amulticenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT liuli amulticenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT maojianchun amulticenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT xiaolianbo amulticenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT guxiaohua amulticenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT yaomin amulticenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT cuixuejun amulticenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT shiqi amulticenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT wangyongjun amulticenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT liangqianqian amulticenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT wangyiru multicenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT liuyang multicenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT xizhijie multicenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT yuyang multicenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT liuli multicenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT maojianchun multicenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT xiaolianbo multicenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT guxiaohua multicenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT yaomin multicenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT cuixuejun multicenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT shiqi multicenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT wangyongjun multicenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis
AT liangqianqian multicenterrandomizeddoubleblindplacebocontrolledtrialevaluatingtheefficacyandsafetyofhuangqiguizhiwuwutanggranuleinpatientswithrheumatoidarthritis